Uterine Fibroids Treatment Devices Market Size & Growth Forecast 2027–2036, By Segments (Technology, Mode of Treatment), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Uterine Fibroids Treatment Devices Market size was estimated at USD 8.4 billion in 2026 and is projected to grow at a 8.93% CAGR from 2027 to 2036, surpassing USD 19.76 billion by 2036. The industry revenue for 2027 is assessed at USD 9.03 billion.
Get more details on this report
Request Free Sample ReportUterine Fibroids Treatment Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 51.09% market share in 2026, supported by established gynecology care pathways, broad minimally invasive treatment access, and strong adoption of device-based procedures.
- Asia Pacific is projected to grow at a 10.74% CAGR, driven by expanding women's healthcare access, wider minimally invasive procedure adoption, rising patient awareness, and healthcare infrastructure development.
Segment Momentum
- Surgical techniques accounted for 36.04% of the market in 2026 because they remain widely used for complex fibroid cases requiring definitive tissue removal, supported by established clinical practice and physician familiarity.
- Non-invasive treatment is expanding fastest as patients and providers increasingly prefer options that minimize physical trauma, reduce recovery demands, and better support patient-centered fibroid management.
Market Expansion Drivers
- Rising prevalence of uterine fibroids among reproductive-age women driving treatment device demand.
- Preference for minimally invasive procedures improving adoption of advanced fibroid treatment devices.
- Growth of robotic-assisted and image-guided therapies enhancing precision gynecological treatment outcomes.
Leading Market Participants
- Top players in the uterine fibroids treatment devices market include Medtronic plc (Ireland), Stryker Corporation (United States), Boston Scientific Corporation (United States), Insightec Ltd. (Israel), CooperSurgical Inc. (United States), Hologic, Inc. (United States), CONMED Corporation (United States), Gynesonics, Inc. (United States), Merit Medical Systems, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 8.4 billion
- 2027 Estimated Market Size: USD 9.03 billion.
- Projected Market Size: USD 19.76 billion by 2036
- Growth Forecast: 8.93% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Surgical Techniques (Technology) | Invasive Treatment (Mode of Treatment)
- Emerging Opportunity Segment: Ablation Techniques (Technology) | Non-invasive Treatment (Mode of Treatment)
Market Growth Drivers and Industry Trends
Rising prevalence of uterine fibroids among reproductive-age women driving treatment device demand
The increasing occurrence of uterine fibroids among women of reproductive age will drive the uterine fibroids treatment devices market growth as more patients require effective management of symptoms and disease-related complications. Fibroids can contribute to heavy menstrual bleeding, pelvic discomfort, reproductive difficulties, and other quality-of-life concerns, creating demand for interventions tailored to disease severity and patient circumstances. Greater awareness of gynecological health and improved access to diagnostic evaluation are also helping identify patients who may benefit from device-based treatment approaches.
Preference for minimally invasive procedures improving adoption of advanced fibroid treatment devices
Growing patient and clinician preference for procedures that reduce surgical trauma is supporting adoption within the uterine fibroids treatment devices market. Minimally invasive approaches can offer advantages such as smaller incisions or non-incisional treatment pathways, reduced recovery requirements, and greater suitability for patients seeking alternatives to more extensive surgery. Improvements in device design and procedural techniques are enabling healthcare providers to target fibroid tissue more effectively while preserving surrounding structures, supporting broader consideration of device-based interventions in appropriate clinical settings.
Growth of robotic-assisted and image-guided therapies enhancing precision gynecological treatment outcomes
The integration of robotics, advanced imaging, and real-time procedural guidance is strengthening the uterine fibroids treatment devices market by enabling clinicians to perform increasingly precise interventions. Image-guided systems can help physicians locate and characterize fibroid tissue while supporting accurate treatment delivery, whereas robotic assistance can improve instrument control and procedural consistency during selected interventions. These technologies are also contributing to more tailored treatment strategies by helping clinicians account for fibroid location, size, and anatomical characteristics when planning and executing procedures.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of uterine fibroids among reproductive-age women driving treatment device demand | 2.30% | High | North America, Europe | High | Near Term |
| Preference for minimally invasive procedures improving adoption of advanced fibroid treatment devices | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Growth of robotic-assisted and image-guided therapies enhancing precision gynecological treatment outcomes | 1.70% | High | Europe, North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the uterine fibroids treatment devices market with a 51.09% share in 2026, reflecting advanced gynecological healthcare infrastructure, high awareness of uterine fibroids, and strong access to minimally invasive treatment options. Healthcare providers increasingly favor device-based interventions that can offer effective symptom management while reducing procedural burden and supporting faster recovery. Continued development of minimally invasive technologies, established specialist care networks, and strong healthcare expenditure are reinforcing the region's adoption of advanced treatment devices.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, supported by expanding healthcare infrastructure, increasing awareness of women's health conditions, and improving access to specialized gynecological care. Greater recognition of uterine fibroids and rising demand for less invasive treatment approaches are encouraging healthcare facilities to adopt advanced therapeutic devices. Growing investment in hospital capabilities and improvements in diagnostic and treatment access are also creating a stronger environment for market expansion across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Technology IntegrationGermany prioritizes uterine fibroids treatment devices supported by strong clinical evidence and integration into hospital-based gynecological care. Healthcare providers focus on technologies that improve procedural efficiency and enhance patient outcomes through minimally invasive approaches.
France 🇫🇷
Hospital-Based InnovationFrance supports uterine fibroids treatment devices through structured hospital care and growing adoption of less invasive therapeutic options. French healthcare providers prioritize technologies that balance clinical effectiveness, patient safety, and efficient procedural workflows.
Italy 🇮🇹
Specialist Procedure ExpansionItaly continues strengthening access to uterine fibroids treatment devices through specialized gynecological centers and wider adoption of minimally invasive interventions. Italian healthcare providers focus on technologies that enhance treatment precision while supporting improved patient recovery.
Japan 🇯🇵
Precision Treatment PathwaysJapan encourages adoption of uterine fibroids treatment devices that provide accurate targeting and preserve reproductive health where appropriate. Healthcare institutions emphasize advanced procedural techniques that align with individualized treatment planning and clinical quality standards.
South Korea 🇰🇷
Advanced Women's CareSouth Korea continues expanding the use of uterine fibroids treatment devices through modern gynecological services and minimally invasive treatment options. Healthcare providers increasingly adopt innovative technologies that improve procedural efficiency and patient experience.
United States 🇺🇸
Minimally Invasive AdoptionThe U.S. uterine fibroids treatment devices market emphasizes minimally invasive procedures that reduce recovery time while preserving treatment effectiveness. Healthcare providers continue expanding access to advanced device technologies that support personalized patient care.
Segment Leadership and Growth Trends
Uterine Fibroids Treatment Devices Market Share (%), by Technology, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Segment Analysis: Surgical Techniques (Largest Segment) vs Ablation Techniques (Fastest-Growing Segment)
Surgical techniques held the largest share of 36.04% in 2026 in the uterine fibroids treatment devices market, supported by their established clinical role in treating symptomatic fibroids and their suitability for a broad range of disease presentations. Surgical approaches provide physicians with direct treatment options for removing or addressing fibroid tissue, making them an important part of conventional gynecological care. Ablation techniques are advancing more rapidly as clinicians and patients increasingly seek uterus-preserving and less invasive alternatives that can reduce procedural burden while effectively managing symptoms. Continued development of energy-based technologies and greater emphasis on personalized treatment approaches are supporting adoption of ablation-based procedures.
Mode of Treatment Segment Analysis: Invasive Treatment (Largest Segment) vs Non-invasive Treatment (Fastest-Growing Segment)
Invasive treatment accounted for the largest share in 2026, reflecting the established use of procedural interventions for patients requiring definitive management of symptomatic uterine fibroids. These approaches can provide direct and effective treatment for fibroid-related symptoms and remain important when medication or less invasive options are insufficient. Non-invasive treatment is gaining momentum at a faster pace as treatment preferences increasingly favor approaches that minimize procedural trauma, recovery requirements, and disruption to daily activities. Advances in image-guided and energy-based technologies are broadening the potential for non-invasive management while supporting greater patient acceptance of alternatives to conventional procedures.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques | Surgical Techniques | Ablation Techniques |
| Mode of Treatment | Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment | Invasive Treatment | Non-invasive Treatment |
Competitive Landscape and Market Positioning
Major players in the uterine fibroids treatment devices market:
1. Medtronic plc (Ireland)
2. Stryker Corporation (United States)
3. Boston Scientific Corporation (United States)
4. Insightec Ltd. (Israel)
5. CooperSurgical Inc. (United States)
6. Hologic Inc. (United States)
7. CONMED Corporation (United States)
8. Gynesonics Inc. (United States)
9. Merit Medical Systems Inc. (United States)
Growing demand for minimally invasive gynecological procedures is accelerating innovation within the uterine fibroids treatment devices market. Companies are developing advanced ablation systems, image-guided treatment technologies, and fertility-preserving solutions aimed at improving patient outcomes. Strategic expansion activities and increasing investment in women’s health technologies are also contributing to rapid product development and broader treatment accessibility.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic plc (Ireland) | |||||||
| Stryker Corporation (United States) | |||||||
| Boston Scientific Corporation (United States) | |||||||
| Insightec Ltd. (Israel) | |||||||
| CooperSurgical Inc. (United States) | |||||||
| Hologic Inc. (United States) | |||||||
| CONMED Corporation (United States) | |||||||
| Gynesonics Inc. (United States) | |||||||
| Merit Medical Systems Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Gynesonics | Sep-24 | The company released SMART OS 2.4 software for its Sonata System, featuring an upgraded SMART Guide that reduces the minimum ablation zone size. This innovation provides clinicians with higher precision and improved control for treating smaller, harder-to-reach fibroids while preserving healthy uterine tissue, enhancing the efficacy of incision-free, transcervical fibroid management. |
| Medtronic | Nov-22 | The company launched the TruClear hysteroscopic tissue removal system and HysteroLux fluid management system in the Indian market. This technology provides a mechanical, non-thermal alternative to traditional electrosurgical methods, enabling the precise and safe removal of intrauterine fibroids and polyps while minimizing the risk of uterine scarring and supporting organ-preservation goals. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Uterine Fibroids Treatment Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Fibroid Type | Intramural Fibroids, Submucosal Fibroids, Subserosal Fibroids, Pedunculated Fibroids |
| Procedure Setting | Inpatient Procedures, Outpatient Procedures, Ambulatory Procedures |
| Healthcare Facility Type | Hospitals, Ambulatory Surgical Centers, Specialty Clinics |
Uterine Fibroids Treatment Devices Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Patient Treatment Pathway & Referral Pattern Assessment |
|
| Hospital Procurement & Capital Purchasing Analysis |
|
| Unmet Clinical Needs & Innovation Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchHow large is the uterine fibroids treatment devices market?
How will the uterine fibroids treatment devices industry grow in terms of size and CAGR by 2036?
Why are minimally invasive procedures accelerating demand in the uterine fibroids treatment devices market?
How are robotic-assisted and image-guided technologies influencing investment decisions in the uterine fibroids treatment devices market?
Why do surgical techniques hold the largest share of the uterine fibroids treatment devices market?
Why is non-invasive treatment the fastest-growing mode in the uterine fibroids treatment devices market?
Why does North America dominate the uterine fibroids treatment devices market?
What is driving rapid growth in the uterine fibroids treatment devices market across Asia Pacific?
Who holds a significant market share in the uterine fibroids treatment devices landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization